Tourette's syndrome: are stimulants safe?

Area of Science:

• Pediatric Neurology
• Child Psychiatry
• Neurodevelopmental Disorders

Background:

• Comorbid attention deficit hyperactivity disorder (ADHD) and Tourette syndrome (TS) present complex treatment challenges.
• Historically, psychostimulants were contraindicated in ADHD/TS due to concerns about exacerbating tics, based on anecdotal evidence.
• Recent research has begun to re-evaluate the safety and efficacy of stimulant use in this population.

Purpose of the Study:

• To evaluate the efficacy and safety of stimulant medications for treating ADHD in children with comorbid Tourette syndrome.
• To investigate whether stimulant treatment for ADHD impacts tic severity in children with co-occurring ADHD and TS.
• To compare the tolerability of different stimulant compounds in this specific patient group.

Main Methods:

• Systematic review and meta-analysis of placebo-controlled, double-blinded clinical trials.
• Inclusion of studies specifically examining children with diagnosed ADHD and Tourette syndrome.
• Assessment of ADHD symptom improvement, tic severity changes, and adverse event profiles.

Main Results:

• Certain stimulant medications, including methylphenidate and dextroamphetamine, demonstrate efficacy in treating ADHD symptoms in children with TS.
• These stimulants are generally well-tolerated in this population.
• Methylphenidate was observed to be particularly well-tolerated, with some studies noting a reduction in tic frequency during treatment.

Conclusions:

• Stimulant therapy is a viable and safe option for managing ADHD in children with comorbid Tourette syndrome.
• Concerns regarding stimulant-induced tic worsening are not consistently supported by current evidence from rigorous clinical trials.
• Methylphenidate may be a preferred stimulant choice due to its favorable tolerability and potential to reduce tics.